What is the survival rate of patients treated with Glofitamab (anti-CD20 monoclonal antibody)?

From the Guidelines

Glofitamab has demonstrated significant survival benefits in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a median overall survival of approximately 18.1 months, as reported in the NP30179 study 1. The efficacy of glofitamab is attributed to its bispecific antibody design, which targets CD20 on B cells and CD3 on T cells, facilitating the elimination of malignant B cells.

• Key findings from the NP30179 study include:
  • A 12-month overall survival rate of about 61%
  • A complete response rate of 39.4%, with most complete responses being durable
• The recommended dosing regimen for glofitamab involves a step-up approach, starting with 2.5 mg on day 1 of cycle 1,10 mg on day 8 of cycle 1, and then 30 mg on day 15 of cycle 1, followed by 30 mg in cycles 2-12.
• Premedication with obinutuzumab is recommended 7 days before the first glofitamab dose to reduce the risk of cytokine release syndrome, a common serious adverse event associated with glofitamab treatment 1.
• Other common side effects of glofitamab include neutropenia, fever, and hypogammaglobulinemia.
• The study's findings suggest that glofitamab is a valuable treatment option for patients with relapsed or refractory DLBCL, offering improved survival outcomes and durable complete responses.

From the Research

Glofitamab Survival Overview

• Glofitamab is a bispecific antibody targeting CD20 and CD3, approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines 2, 3, 4, 5, 6.
• The median overall survival (OS) for patients treated with glofitamab varies across studies:
  • 5.7 months in a multinational real-world study 2.
  • 8.8 months in a real-world study in Turkey 4.
  • Not explicitly stated in the other studies, but progression-free survival (PFS) and response rates are reported.

Response Rates and Survival

• The overall response rate to glofitamab is:
  • 47% in a multinational real-world study, with 27% achieving complete responses (CR) and 20% partial responses (PR) 2.
  • 56% in a multicenter study in Taiwan, with 23% achieving complete remission 3.
  • 39% in a phase 2 study, with 35% of patients who had previously received chimeric antigen receptor T-cell therapy achieving a complete response 5.
• The median PFS is:
  • 3.6 months in a multinational real-world study 2.
  • 3.2 months in a multicenter study in Taiwan 3.
  • 3.3 months in a real-world study in Turkey 4.
• The estimated 1-year PFS is:
  • 33% for the entire cohort in a multicenter study in Taiwan 3.
  • 37% in a phase 2 study 5.
  • 83% for treatment-responsive patients in a real-world study in Turkey 4.

Safety Profile

• The most common adverse events associated with glofitamab are:
  • Cytokine release syndrome (CRS) 2, 3, 5, 6.
  • Immune effector cell-associated neurotoxicity syndrome (ICANS) 2.
  • Infections 2.
  • Hematological toxicity 4.
• The safety profile of glofitamab is considered manageable, with most adverse events being grade 1 or 2 2, 3, 5, 6.